The OIG has created a “spotlight page” on its website to highlight its reports and findings involving the Medicaid drug rebate program. The page features comparisons of drug spending under Medicaid and Medicare Part D, manufacturer compliance with Average Manufacturer Price reporting requirements, manufacturer development of new versions of existing brand-name drugs to minimize rebate obligations, and state collection of drug rebates, among other issues. Another new spotlight page concentrates on OIG investigations involving the IHS program. Previous OIG spotlight pages have focused on independent diagnostic testing facilities, hospice care, power wheelchairs, and Medicaid personal care services.